BMS-986553 for Adults With Autoimmune Diseases That Have Not Responded to Treatment
Tests the safety of BMS-986553 in adults with hard-to-treat autoimmune diseases.
Plain-language title generated from the registry record
Registry title: A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Key facts
- Where
- Ann Arbor, Great Neck, Morristown, Newport Beach, Omaha, Philadelphia, Saint Paul, Salt Lake City, Seattle, and Worcester, United StatesSee the 11 sites
- Phase
- Phase 1
Where in United States
- Ann ArborAnn Arbor, United StatesNo longer taking part
- Great NeckGreat Neck, United StatesNo longer taking part
- MorristownMorristown, United StatesNo longer taking part
- Newport BeachNewport Beach, United StatesNo longer taking part
- OmahaOmaha, United StatesNo longer taking part
- PhiladelphiaPhiladelphia, United StatesNo longer taking part
- Saint PaulSaint Paul, United StatesNo longer taking part
- Salt Lake CitySalt Lake City, United StatesNo longer taking part
- SeattleSeattle, United StatesNo longer taking part
- SeattleSeattle, United StatesNo longer taking part
- WorcesterWorcester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07873931
- Record updated
- 14 October 2026
- Original description
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).Read full original descriptionShow less
A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).
Inclusion: SLE participants: Must have diagnosis of SLE defined as fulfilling the 2019 ACR/EULAR classification criteria of SLE; IIM participants: Must have diagnosis of IIM defined as fulfilling the 2017 ACR/EULAR classification criteria for probable or definite IIM; SSc participants: Must have diagnosis of SSc defined as fulfilling 2013 ACR/EULAR classification criteria for SSc; RA participants: Must have diagnosis of RA, defined as fulfilling 2010 ACR/EULAR criteria for RA; Primary SjD Participants: Must have diagnosis fulfilling the 2016 ACR/EULAR Classification Criteria.
Exclusion: Participants must not have other systemic immune disorders. Other protocol-defined Inclusion/Exclusion criteria apply.